Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
Rho GTPase signaling in cancer progression and dissemination
E Crosas-Molist, R Samain… - Physiological …, 2022 - journals.physiology.org
Rho GTPases are a family of small G proteins that regulate a wide array of cellular
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …
[HTML][HTML] RHOJ controls EMT-associated resistance to chemotherapy
M Debaugnies, S Rodríguez-Acebes, J Blondeau… - Nature, 2023 - nature.com
The resistance of cancer cells to therapy is responsible for the death of most patients with
cancer. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to …
cancer. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to …
BRAF—a tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
[HTML][HTML] Targeted therapy in melanoma and mechanisms of resistance
The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities
Epithelial–mesenchymal transition (EMT) is a program wherein epithelial cells lose their
junctions and polarity while acquiring mesenchymal properties and invasive ability …
junctions and polarity while acquiring mesenchymal properties and invasive ability …
Rac1, a potential target for tumor therapy
J Liang, L Oyang, S Rao, Y Han, X Luo, P Yi… - Frontiers in …, 2021 - frontiersin.org
RAS-related C3 botulinum toxin substrate 1 (Rac. 1) is one of the important members of Rho
GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell …
GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell …
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Abstract Small GTPases including Ras, Rho, Rab, Arf, and Ran are omnipresent molecular
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …
[HTML][HTML] Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review
I Proietti, N Skroza, N Bernardini, E Tolino, V Balduzzi… - Cancers, 2020 - mdpi.com
Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …